According to the company’s last quarterly earnings report, USOncology is affiliated with 1,227 physicians operating in 468 locations,including 95 radiation oncology facilities in 39 states. For more information,visit the company’s Web site, Oncology, Inc.Media, Jennifer Horspool, US Oncology, Inc., +1-281-863-6739, +1-949-933-4300,. US Oncology uses its expertise to support every aspect of the cancer caredelivery system–from drug development to distribution and outcomesmeasurement–enabling the company to help increase the efficiency and safetyof cancer care. US Oncology supports one of thenation’s foremost cancer treatment and research networks, accelerating theavailability and use of evidence-based medicine and shared best practices. US Oncology Research servesmore than 80 sites in 200 locations with over 70 open trials being managed atany given time.

Additionally, the research network has accrued over 38,500 patients since itsinception and contributed to the development of 36 of the latestcancer-fighting drugs approved by the FDA. For more information, visit the USOncology Research section under About US Oncology on the company’s Web site, US OncologyUS Oncology, Inc., headquartered in The Woodlands, Texas, works closely withphysicians, payers, biotechnology, pharmaceutical and medical equipmentmanufacturers, to identify and deliver innovative services that enhancepatient access to advanced cancer care. BSI-201 + G/C was well tolerated withadverse events (AEs) consistent with known safety profiles of G/C regimens.J Clin Oncol 27:18s, 2009 (suppl; abstr 3) About US Oncology Research With experienced investigators and dedicated research nurses, US OncologyResearch represents the largest research network specializing in Phase I-IVoncology clinical trials in the United States. Patientsmust have measurable metastatic breast cancer with zero to two priorchemotherapy regimens for metastatic disease; adjuvant chemotherapy isallowed. Patients interested in learning more about participation shouldcontact Laura Guerra, RN, CCRC, director of Research Clinical Operations andWomen’s Oncology and Early Phase Research with US Oncology at 281-863-1000 orvisit Primary objectives of the study are to evaluate: overall survival (OS),progression-free survival (PFS), the objective response rate (ORR), and tofurther evaluate the safety and tolerability of BSI-201 in combination withgemcitabine and carboplatin.Phase II of the study in triple negative breast cancer patients found thatBSI-201 + G/C resulted in a statistically and clinically significantimprovement in clinical benefit rate (CBR), median progression-free survival(PFS) and OS, compared with G/C alone. Enrollment in the study opened July 16in centers nationwide.”The BSI-201 PARP Inhibitor is a potential game changing therapy in thetreatment of triple-negative breast cancer. US Oncology Research is excitedabout the opportunity to continue our development collaboration with BiPar onthis important potential new therapy,” said Steve Smith, vice president andgeneral manager of Research and Personalized Science for US Oncology Research.”We are eager to leverage the US Oncology Research network to support thestudy.”Patients targeted for the study include adults with histologically documentedbreast cancer that is ER-negative, PR-negative, and HER2- non-overexpressingafter treatment with gemcitabine/carboplatin with or without BSI-201.

BiPar is a wholly owned subsidiary of Paris-basedsanofi-aventis. “Our primary focus now is enrolling patients in this trialwith a similar sense of urgency.” Physicians within the US Oncology network are expected to enroll more than 100participants in this 420-patient study. By inhibiting the enzymatic activity ofPARP, BSI-201 significantly enhances the anti-tumor effects of chemotherapyand has shown promising safety and efficacy results in patients with solidtumors.”We are extremely pleased to be launching the Phase 3 clinical trial sorapidly after the close of the Phase 2 trial,” said Barry Sherman, M.D., headof clinical development at South San Francisco-based BiPar Sciences, which isdeveloping BSI-201. “We expect that accrual will be very rapidwithin the US Oncology network and hope that this trial will lead to rapid FDAapproval of what appears so far to be a well tolerated and effective therapy.” BSI-201 targets PARP, or poly (ADP-ribose) polymerase, a key enzyme involvedin DNA repair and cell proliferation.

SammonsCancer Center and Texas Oncology, a US Oncology affiliate in Dallas, Texas,will lead the study as a follow-up to the Phase II study presented in aplenary session at the 45th Annual Meeting of the American Society of ClinicalOncology (ASCO) held May 29-June 2, 2009, in Orlando, Fla.”We are very pleased to be participating in this clinical trial of BSI-201which is a very promising new treatment for metastatic triple negative breastcancer,” says Dr O’Shaughnessy. todayannounced that US Oncology Research will participate in the BiPar Sciences’Phase III, Multi-center, Open-Label, Randomized Trial ofGemcitabine/Carboplatin (G/C), with or without BSI-201, in patients withEstrogen Receptor (ER), Progesterone Receptor (PR), and HER2-negativemetastatic breast cancer.Joyce O’Shaughnessy, M.D., co-chair of the US Oncology Breast Cancer ResearchCommittee, associate director for clinical research for US Oncology andco-director of the Breast Cancer Research Program at Baylor-Charles A. Shares in TomTom, which traded at 6.4 euros as of 1415 GMT,have recovered from an all-time low of 2.12 euros set in March,on a string of positive news, including the rights offering andnews that it would offer a navigation application for Apple’s(AAPL.O) iPhone.In the same period, Amsterdam’s blue chip index .AEX hasrecovered about 30 percent. Stocks Media. US Oncology Research Network Participates in Phase III Follow-up Study toBiPar’s Investigational Cancer Drug BSI-201Phase II of the trial was presented in 2009 ASCO Plenary Session THE WOODLANDS, Texas, July 20 /PRNewswire/ — US Oncology, Inc. He also said TomTom may announce another in-car contract.The company already has a contract with French carmaker Renault(RENA.PA). TomTom, which is struggling with 1.16 billion euros of debtafter its purchase of Dutch digital map maker Tele Atlas for 2.9billion euros last year, has raised 430 million euros from arights issue and a private placing, to reduce its debt load.

The company, which competes with U.S.-based Garmin Ltd(GRMN.O), can now shift its focus fully to its operations again,analysts said. SNS Securities analyst Martijn den Drijver said his focuswould be on costs “How much more can we expect in the comingquarter?” he said. “Given the weak numbers in the first quarter and the alreadycommunicated shortfall in the second quarter, the likelihoodthat the original guided range is lowered, is significant,”Petercam analyst Eric de Graaf said. [ID:nLG299838] Earlier this month, TomTom said guidance for 11-12 millionPND sales in 2009, and revenue of between 1.4 and 1.6 billioneuros, remained “challenging in light of low consumer spending”.